Table 1

Anthropometric parameters and blood pressure before and after intervention
Placebo (n = 19) Low-dose (n = 19) High-dose (n = 19) Pa)
Age (yr) 37.0 ± 2.24 36.4 ± 1.73 35.3 ± 1.68 0.910
Male / Female (n) 7/12 7/12 9/10 0.747
Body mass index (BMI; kg/m2)
 Pre-treatment 23.4 ± 0.60 24.0±0.93 23.5±0.70
 Post-treatment 23.6 ± 0.67 24.3±0.93 23.6±0.65
 Change 0.27±0.16 0.26±0.15 0.11±0.14 0.850
Cigarette smoker, n (%) 8 (42.1) 6 (31.6) 8 (42.1) 0.948
Alcohol drinker, n (%) 15 (78.9) 13 (68.4) 13 (68.4) 0.706
Blood pressure (mmHg)
Systolic blood pressure (mmHg)
 Pre-treatment 115.3±2.92 118.8±3.22 117.5±2.32
 Post-treatment 114.7±2.08 118.8±3.10 118.2±1.94
 Change −0.55±1.97 −0.03±0.19 0.74±1.65 0.740
Diastolic blood pressure (mmHg)
 Pre-treatment 76.6±1.83 80.6±1.98 78.4±1.81
 Post-treatment 75.6±1.93 77.3±2.14* 76.2±1.71
 Change −0.92±1.88 −3.29±1.28 −2.16±1.75 0.599

Results are expressed as mean ± standard error of the mean (SEM) or n (%).

Baseline values for the placebo and test groups were not significantly different (nonparametric Kruskal-Wallis test).

*P < 0.05 compared with the baseline in each group (Wilcoxon signed-rank test).

a) Evaluated by nonparametric Kruskal-Wallis test.

Kim et al.

Kim et al. Nutrition Journal 2012 11:47   doi:10.1186/1475-2891-11-47

Open Data